Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Several studies show that a measles infection can suppress the immune system for up to three years, making people susceptible ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Researchers Uncover Key Missing Link in Understanding Autoimmune DisordersAutoimmune diseases, which are estimated to affect ...

Experts said there’s no conclusive evidence that a measles infection boosts a person’s immune system later in life against cancer, heart disease or atopic diseases. Several studies show that a measles ...

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the enrollment of the first patient in a ...

BiomX (NYSEAMERICAN:PHGE – Get Free Report) is anticipated to announce its earnings results before the market opens on ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

During the March 4 episode, Fox’s chief medical analyst ... It boosts your immune system later in life against cancers, atopic diseases, cardiac disease, etc. It's not well-studied.

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission Novel mechanism of action suggests SYX-5219 has potential across broad range of inflammatory diseases ...